How can I remove the spots on both sides of my cheeks?

Facial hyperpigmentation—commonly referred to as “sun spots,” “age spots,” or “melasma”—can appear on the cheeks due to a combination of factors, including chronic sun exposure, hormonal fluctuations (e.g., during pregnancy or with oral contraceptive use), genetic predisposition, and post-inflammatory changes following acne or skin injury. Effective management requires a multifaceted approach grounded in evidence-based dermatology.

First and foremost, rigorous daily photoprotection is non-negotiable. Use a broad-spectrum sunscreen with SPF 30 or higher, containing physical blockers like zinc oxide or titanium dioxide—or modern, photostable chemical filters such as Tinosorb S/M, Mexoryl SX/XL, or Uvinul A Plus. Reapply every two hours when outdoors, and pair sunscreen with wide-brimmed hats and UV-protective sunglasses. Without consistent sun protection, all other interventions are likely to fail or result in recurrence.

Topical therapies form the cornerstone of treatment. Prescription-strength hydroquinone (4%) remains a first-line agent for epidermal pigmentation, typically used for 8–12 weeks under dermatologic supervision to minimize risks of ochronosis or rebound hyperpigmentation. Alternatives include triple-combination creams (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%), azelaic acid 15–20%, tranexamic acid 5% cream, niacinamide 4–5%, and cysteamine 5%. These agents work via distinct mechanisms—including tyrosinase inhibition, anti-inflammatory effects, and modulation of melanocyte activity—and may be tailored based on skin type, pigment depth, and comorbidities such as sensitive or melasma-prone skin.

For persistent or dermal pigment, procedural interventions may be considered—but only after optimizing topical care and sun protection. Options include low-fluence Q-switched Nd:YAG laser (1064 nm), picosecond lasers, fractional non-ablative resurfacing (e.g., 1550 nm erbium-doped fiber laser), and tranexamic acid mesotherapy or iontophoresis. Importantly, aggressive treatments like ablative lasers or high-energy devices carry significant risk of post-inflammatory hyperpigmentation—especially in Fitzpatrick skin types III–VI—and should be performed exclusively by experienced dermatologists with expertise in pigmentary disorders.

Lifestyle and systemic considerations also matter. Hormonal evaluation may be warranted in women with new-onset or worsening malar pigmentation, particularly if associated with menstrual irregularities or other signs of endocrine dysfunction. Oral tranexamic acid (250 mg twice daily) has demonstrated efficacy in refractory melasma but requires careful risk-benefit assessment due to its antifibrinolytic properties and contraindications (e.g., history of thromboembolism, stroke, or estrogen-sensitive malignancy).

Patience and realistic expectations are essential: improvement typically takes 3–6 months, and maintenance therapy is often lifelong. Regular follow-up with a board-certified dermatologist ensures safe, individualized care and timely adjustment of strategy based on clinical response and tolerability.